Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. (Collegium Pharmaceutical) is a privately held specialty pharmaceutical company. The company primarily focuses on late-stage development, and commercialization of prescription pharmaceuticals for the treatment of central nervous system (CNS), respiratory and skin related disorders. The products incorporate the proprietary technologies, delivery systems and innovative regulatory strategies. The company applies customized pharmaceutical formulations and IP (intellectual property) strategies to active ingredients. In addition, the company, through its subsidiary, Onset Therapeutics, is engaged in the development and commercialization of products for skin and skin related disorders using its novel DELEVO Foam Technology. The company has sold all worldwide rights of AllerNaze (triamcinolone acetonide, USP) Nasal Spray, 50 mcg to Lupin Ltd., an innovation led transnational pharmaceutical company. It further completed the spin-out of its subsidiary Onset Therapeutics, LLC, which will operate as a part of PreCision Dermatology, Inc., its newly formed company. Collegium Pharmaceutical is headquartered in Rhode Island, the US.